NCT04586088进行中（未招募）2 期
Apatinib Combined With Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Failed at Least the First-line Treatment
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2020年5月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 58
- 试验地点
- 1
- 主要终点
- Objective response rate
研究概览
简要总结
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female; 18-70 years of age.
- •Subjects diagnosed with pathological confirmed metastatic nasopharyngeal carcinoma, or subjects with recurrent NPC that is unfit for local treatment
- •Underwent at least first-line treatment failure
- •ECOG performance status of 0 or
- •Life expectancy more than 12 weeks.
- •Subjects enrolled must have measurable lesion(s) according to response evaluation criteria in solid (RECIST) v1.
- •Adequate organ function assessed by laboratory parameters during the screening period.
- •Female subjects agree not to be pregnant or lactating from beginning of the study screening through at least 3 months after receiving the last dose of study treatment. Both men and women of reproductive potential must be willing and able to employ a highly effective method of birth control/contraception to prevent pregnancy.
- •Able to understand and sign an informed consent form (ICF).
排除标准
- •Subjects with any active autoimmune disease or history of autoimmune disease, or history of syndrome that requires systemic steroids or immunosuppressive medications, including but not limited to the following: rheumatoid arthritis, pneumonitis, colitis (inflammatory bowel disease), hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Subjects with the following conditions will not be excluded from this study: asthma that requires intermittent use of bronchodilators, hypothyroidism stable on hormone replacement, vitiligo, Graves' disease, or Hashimoto's disease. Additional exceptions may be made with medical monitor approval;
- •Known history of hypersensitivity to any components of the Camrelizumab formulation or other monoclonal antibodies ;
- •Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses 10 mg/day prednisone or equivalent are prohibited within 4 weeks before study drug administration. Note: corticosteroids used for the purpose of IV contrast allergy prophylaxis are allowed;
- •Subjects who underwent anti-PD-1 /PD-L antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs.
- •Abnormal coagulation function (INR>1.5×ULN, APTT>1.5×ULN) with bleeding tendency.
- •The laboratory test values within 7 days before enrollment do not meet the relevant standards.
- •Active central nervous system (CNS) metastases (indicated by clinical symptoms, cerebral edema, steroid requirement, or progressive disease);
- •Diagnosed with other malignant tumors.
- •Uncontrolled clinically significant medical condition, including but not limited to the following:
- •Hypertension that cannot be reduced to the normal range after antihypertensive drug
- •congestive heart failure (New York Health Authority Class > 2),
- •unstable angina,
- •myocardial infarction within the past 12 months,
- •clinically significant supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention;
- •Active bleeding, ulcer, intestinal perforation, major surgery in the previous month; Patients with tumors close to the internal carotid artery or other large vessels, thus at risk of massive bleeding
- •Active infection or an unexplained fever; 38.5°C during screening visits or on the first scheduled day of dosing (at the discretion of the investigator, subjects with tumor fever may be enrolled);
- •History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease; active tuberculosis (TB), anti-TB treatment is ongoing or within 1 year prior to screening; Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation based on institutional guidelines and tests. Testing may include the following: HBV DNA, HCV RNA, hepatitis B surface antigen, or anti-Hepatitis B core antibody.
- •Received any anti-infective vaccine (e.g. influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment.
- •Any other medical (eg, pulmonary, metabolic, congenital, endocrinal, or CNS disease), psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate, and participate in the study or would interfere with the interpretation of the results;
研究组 & 干预措施
Apatinib plus Camrelizumab arm
Experimental
Subjects receive apatinib plus camrelizumab
干预措施: Apatinib plus Camrelizumab (Drug)
结局指标
主要结局
Objective response rate
时间窗: 1 year
Defined as the proportion of patients whose tumors shrink to complete response (CR) or partial response (PR) and remain for a certain period of time according to RECIST 1.1
次要结局
- The proportion of patients who achieved disease control(1 year)
- median progression-free survival(1 year)
- The proportion of patients who achieved clinical benefit(1 year)
- Adverse events(1 year)
- Duration of response(1 year)
研究者
Ming-Yuan Chen
Chief physician, Proffessor
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaResectable Hepatocellular CarcinomaNCT04701060Tianjin Medical University Cancer Institute and Hospital31
Unknown
2 期
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric AdenocarcinomaAdvanced Gastric CarcinomaNCT04948125Henan Cancer Hospital20
已完成
2 期
Camrelizumab Combined With Apatinib for Recurrent Resistant GTNGestational Trophoblastic DiseaseNCT04047017Peking Union Medical College Hospital20
尚未招募
2 期
Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaNCT05189184The First Affiliated Hospital of Zhengzhou University30
Unknown
2 期
Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung CancerSmall Cell Lung CarcinomaNCT04901754Henan Cancer Hospital38